Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 3/2019

01-03-2019 | Peritoneal Dialysis | Nephrology - Original paper

Associations of vitamin K status with mortality and cardiovascular events in peritoneal dialysis patients

Authors: Qingdong Xu, Huankai Guo, Shirong Cao, Qian Zhou, Jiexin Chen, Ming Su, Siying Chen, Songqin Jiang, Xiaofeng Shi, Yueqiang Wen

Published in: International Urology and Nephrology | Issue 3/2019

Login to get access

Abstract

Purpose

Vitamin K deficiency, expressed by a high level of desphospho-uncarboxylated matrix GLA protein (dp-ucMGP), is highly prevalent in dialysis patients. However, the predictive ability of the vitamin K status remains unclear in continuous ambulatory peritoneal dialysis (CAPD) patients.

Methods

158 prevalent CAPD patients with a median level of dp-ucMGP of 1093 (752, 1485) pmol/L were enrolled. Patient outcomes including all-cause mortality and cardiovascular events (CVEs) were recorded during follow-up. Survival curves were performed using Kaplan–Meier method, and the influences of dp-ucMGP on outcomes were analyzed by Cox regression models.

Results

A total of 59 deaths and 82 new episodes of CVEs occurred during median follow-up of 31.4 ± 13.1 months (range: 3.8–48.0 months). Kaplan–Meier analysis revealed patients with higher dp-ucMGP levels (≥ 1093 pmol/L) had an increased risk for both mortality (P = 0.005) and CVEs (P < 0.001). Multivariable Cox regression confirmed that higher dp-ucMGP levels increase the mortality risk [hazard ratio (HR), 1.763; 95% CI 1.045–3.291] and CVEs (HR, 1.846; 95% CI 1.074–3.172). For every 100 pmol/L increase in serum dp-ucMGP, the adjusted HRs for mortality and CVEs were 1.054 (95% CI 1.008–1.106) and 1.034 (95% CI 1.012–1.089), respectively.

Conclusions

Vitamin K deficiency, as expressed by high dp-ucMGP levels, showed independently associations with mortality and CVEs in CAPD patients.
Literature
1.
Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383:1831–1843CrossRefPubMed
2.
Sarnak MJ, Foley RN (2011) Cardiovascular mortality in the general population versus dialysis: a glass half full or empty? Am J Kidney Dis 58:4–6CrossRefPubMed
3.
4.
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18:1731–1740CrossRefPubMed
5.
6.
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81CrossRef
7.
Munroe PB, Olgunturk RO, Fryns JP, Van Maldergem L, Ziereisen F, Yuksel B, Gardiner RM, Chung E (1999) Mutations in the gene encoding the human matrix Gla protein cause keutel syndrome. Nat Genet 21:142–144CrossRefPubMed
8.
Murshed M, Schinke T, McKee MD, Karsenty G (2004) Extracellular matrix mineralization is regulated locally; different roles of two Gla-containing proteins. J Cell Biol 165:625–630CrossRefPubMedPubMedCentral
9.
Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D (2007) Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost 5:2503–2511CrossRefPubMed
10.
Rennenberg RJ, de Leeuw PW, Kessels AG, Schurgers LJ, Vermeer C, van Engelshoven JM, Kemerink GJ, Kroon AA (2010) Calcium scores and matrix Gla protein levels: association with vitamin K status. Eur J Clin Invest 40:344–349CrossRefPubMed
11.
Shea MK, O’Donnell CJ, Vermeer C, Magdeleyns EJ, Crosier MD, Gundberg CM, Ordovas JM, Kritchevsky SB, Booth SL (2011) Circulating uncarboxylated matrix Gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J Nutr 141:1529–1534CrossRefPubMedPubMedCentral
12.
Dalmeijer GW, van der Schouw YT, Vermeer C, Magdeleyns EJ, Schurgers LJ, Beulens JW (2013) Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. J Nutr Biochem 24:624–628CrossRefPubMed
13.
Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewe RB, Brandenburg VM, Bekers O, Vermeer C (2010) Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost 104:811–822CrossRefPubMed
14.
Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ (2012) Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 59:186–195CrossRefPubMed
15.
Theuwissen E, Cranenburg EC, Knapen MH, Magdeleyns EJ, Teunissen KJ, Schurgers LJ, Smit E, Vermeer C (2012) Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects. Br J Nutr 108:1652–1657CrossRefPubMed
16.
Nimptsch K, Rohrmann S, Kaaks R, Linseisen J (2010) Dietary vitamin K intake in relation to cancer incidence and mortality: results from the heidelberg cohort of the european prospective investigation into cancer and nutrition (EPIC-Heidelberg). Am J Clin Nutr 91:1348–1358CrossRefPubMed
17.
Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, Beulens JW (2013) Matrix Gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diabetes Care 36:3766–3771CrossRefPubMedPubMedCentral
18.
Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, Vermeer C, Schurgers LJ (2010) Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med 268:483–492CrossRefPubMed
19.
Mayer OJ, Seidlerova J, Bruthans J, Filipovsky J, Timoracka K, Vanek J, Cerna L, Wohlfahrt P, Cifkova R, Theuwissen E, Vermeer C (2014) Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease. Atherosclerosis 235:162–168CrossRefPubMed
20.
Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ (2011) Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD. J Am Soc Nephrol 22:387–395CrossRefPubMedPubMedCentral
21.
Elliott MJ, Booth SL, Hopman WM, Holden RM (2014) Assessment of potential biomarkers of subclinical vitamin K deficiency in patients with end-stage kidney disease. Can J Kidney Health Dis 1:13CrossRefPubMedPubMedCentral
22.
Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16:1803–1810CrossRefPubMed
23.
Xu Q, Xiong L, Fan L, Xu F, Yang Y, Li H, Peng X, Cao S, Zheng Z, Yang X, Yu X, Mao H (2015) Association of pulmonary hypertension with mortality in incident peritoneal dialysis patients. Perit Dial Int 35:537–544CrossRefPubMedPubMedCentral
24.
Rocco MV, Jordan JR, Burkart JM (1994) Determination of peritoneal transport characteristics with 24-hour dialysate collections: dialysis adequacy and transport test. J Am Soc Nephrol 5:1333–1338PubMed
25.
van Olden RW, Krediet RT, Struijk DG, Arisz L (1996) Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 7:745–750PubMed
26.
Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083CrossRefPubMed
27.
Tarrass F, Benjelloun M, Zamd M, Medkouri G, Hachim K, Benghanem MG, Ramdani B (2006) Heart valve calcifications in patients with end-stage renal disease: analysis for risk factors. Nephrology (Carlton) 11:494–496CrossRef
28.
Choi MJ, Kim JK, Kim SG, Kim SE, Kim SJ, Kim HJ, Song YR (2013) Association between cardiac valvular calcification and myocardial ischemia in asymptomatic high-risk patients with end-stage renal disease. Atherosclerosis 229:369–373CrossRefPubMed
29.
Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, Lui SF, Li PK, Sanderson JE (2005) Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 20:1676–1685CrossRefPubMed
30.
Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, Kaczmarska M, Stefanczyk L, Vermeer C, Maresz K, Nowicki M (2016) Plasma desphospho-uncarboxylated matrix Gla protein as a marker of kidney damage and cardiovascular risk in advanced stage of chronic kidney disease. Kidney Blood Press Res 41:231–239CrossRefPubMed
31.
Fusaro M, Plebani M, Iervasi G, Gallieni M (2017) Vitamin K deficiency in chronic kidney disease: evidence is building up. Am J Nephrol 45:1–3CrossRefPubMed
32.
Dalmeijer GW, van der Schouw YT, Magdeleyns E, Ahmed N, Vermeer C, Beulens JW (2012) The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. Atherosclerosis 225:397–402CrossRefPubMed
33.
Dam V, Dalmeijer GW, Vermeer C, Drummen NE, Knapen MH, van der Schouw YT, Beulens JW (2015) Association between vitamin K and the metabolic syndrome: a 10-year follow-up study in adults. J Clin Endocrinol Metab 100:2472–2479CrossRefPubMed
34.
Caluwe R, Vandecasteele S, Van Vlem B, Vermeer C, De Vriese AS (2014) Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant 29:1385–1390CrossRefPubMed
35.
Fusaro M, D’Alessandro C, Noale M, Tripepi G, Plebani M, Veronese N, Iervasi G, Giannini S, Rossini M, Tarroni G, Lucatello S, Vianello A, Santinello I, Bonfante L, Fabris F, Sella S, Piccoli A, Naso A, Ciurlino D, Aghi A, Gallieni M, Cupisti A (2017) Low vitamin K1 intake in haemodialysis patients. Clin Nutr 36:601–607CrossRefPubMed
36.
Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L, Pottel H, Cavalier E (2014) Dephosphorylated-uncarboxylated matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol 15:145CrossRefPubMedPubMedCentral
37.
Shea MK, Booth SL, Massaro JM, Jacques PF, D’Agostino RS, Dawson-Hughes B, Ordovas JM, O’Donnell CJ, Kathiresan S, Keaney JJ, Vasan RS, Benjamin EJ (2008) Vitamin K and vitamin D status: associations with inflammatory markers in the framingham offspring study. Am J Epidemiol 167:313–320CrossRefPubMed
38.
Boxma PY, van den Berg E, Geleijnse JM, Laverman GD, Schurgers LJ, Vermeer C, Kema IP, Muskiet FA, Navis G, Bakker SJ, de Borst MH (2012) Vitamin K intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. PLoS ONE 7:e47991CrossRefPubMedPubMedCentral
39.
Reddi K, Henderson B, Meghji S, Wilson M, Poole S, Hopper C, Harris M, Hodges SJ (1995) Interleukin 6 production by lipopolysaccharide-stimulated human fibroblasts is potently inhibited by naphthoquinone (Vitamin K) compounds. Cytokine 7:287–290CrossRefPubMed
40.
Ohsaki Y, Shirakawa H, Hiwatashi K, Furukawa Y, Mizutani T, Komai M (2006) Vitamin K suppresses lipopolysaccharide-induced inflammation in the rat. Biosci Biotechnol Biochem 70:926–932CrossRefPubMed
41.
Schurgers LJ Vitamin K (2013) Key vitamin in controlling vascular calcification in chronic kidney disease. Kidney Int 83:782–784CrossRefPubMed
42.
Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA (2010) The circulating inactive form of matrix Gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol 5:568–575CrossRefPubMedPubMedCentral
43.
Vliegenthart R, Hollander M, Breteler MM, van der Kuip DA, Hofman A, Oudkerk M, Witteman JC (2002) Stroke is associated with coronary calcification as detected by electron-beam CT: the rotterdam coronary calcification study. Stroke 33:462–465CrossRefPubMed
44.
Benjamin EJ, Plehn JF, D’Agostino RB, Belanger AJ, Comai K, Fuller DL, Wolf PA, Levy D (1992) Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med 327:374–379CrossRefPubMed
45.
De Marco M, Gerdts E, Casalnuovo G, Migliore T, Wachtell K, Boman K, Dahlof B, Olsen MH, Kizer JR, Devereux RB, de Simone G (2013) Mitral annular calcification and incident ischemic stroke in treated hypertensive patients: the life study. Am J Hypertens 26:567–573CrossRefPubMed
46.
Dalmeijer GW, van der Schouw YT, Magdeleyns EJ, Vermeer C, Verschuren WM, Boer JM, Beulens JW (2014) Circulating desphospho-uncarboxylated matrix gamma-carboxyglutamate protein and the risk of coronary heart disease and stroke. J Thromb Haemost 12:1028–1034CrossRefPubMed
Metadata
Title
Associations of vitamin K status with mortality and cardiovascular events in peritoneal dialysis patients
Authors
Qingdong Xu
Huankai Guo
Shirong Cao
Qian Zhou
Jiexin Chen
Ming Su
Siying Chen
Songqin Jiang
Xiaofeng Shi
Yueqiang Wen
Publication date
01-03-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-019-02080-x

Other articles of this Issue 3/2019

International Urology and Nephrology 3/2019 Go to the issue

Urology - Original Paper

Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy

Urology - Original Paper

Factors determining the sperm retrieval rate in fresh versus salvage micro-TESE: a comparative cohort study

Nephrology - Original Paper

Aspirin attenuates podocyte injury in diabetic rats through overriding cyclooxygenase-2-mediated dysregulation of LDL receptor pathway

Urology - Letter to the editor

Hormonal stimulation of spermatogenesis: a new way to treat the infertile male with non-obstructive azoospermia?

Urology - Original Paper

Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial

Correction

Correction to: Basiliximab versus rabbit antithymocyte globulin as induction therapy for living-related renal transplantation: a single-center experience
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits